Lixisenatide vs Pemvidutide
Head-to-head comparison of Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Lixisenatide | Pemvidutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Exendin-4-derived GLP-1 receptor agonist | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 4858 Da | N/A |
| Half-Life | 2-4 hours | Approximately 1 week |
| Amino Acids | 44 | N/A |
| Typical Dose | 10-20 mcg daily | Trial-dependent; once-weekly SC titration |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 400 | 18 |
| Research Status | Approved | Clinical |
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.